Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RXRX – Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc.
RXRX
$5.68
Name : Recursion Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,467,062,528.00
EPSttm : -1.8
finviz dynamic chart for RXRX
Recursion Pharmaceuticals, Inc.
$5.68
4.54%
$0.27

Float Short %

34.95

Margin Of Safety %

Put/Call OI Ratio

0.41

EPS Next Q Diff

0.19

EPS Last/This Y

0.23

EPS This/Next Y

0.31

Price

5.68

Target Price

6.67

Analyst Recom

2.5

Performance Q

3.27

Relative Volume

0.63

Beta

0.92

Ticker: RXRX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04RXRX5.260.470.64387088
2025-07-07RXRX4.930.470.26379530
2025-07-08RXRX5.360.470.15385790
2025-07-09RXRX5.590.460.07392895
2025-07-10RXRX5.720.440.09402874
2025-07-11RXRX5.280.440.17409157
2025-07-14RXRX5.270.450.13394751
2025-07-15RXRX5.250.450.45399181
2025-07-16RXRX5.390.450.14413072
2025-07-17RXRX5.510.450.67414842
2025-07-18RXRX5.840.450.22423807
2025-07-21RXRX6.350.400.09381385
2025-07-22RXRX6.530.380.07416969
2025-07-23RXRX6.430.380.24423622
2025-07-24RXRX6.240.380.06424952
2025-07-25RXRX6.460.380.10422382
2025-07-28RXRX6.30.400.11400697
2025-07-29RXRX5.950.400.27403721
2025-07-30RXRX5.80.410.19411106
2025-07-31RXRX5.950.410.13415002
2025-08-01RXRX5.670.410.57415782
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04RXRX5.2712.5- -1.46
2025-07-07RXRX4.9312.5- -1.46
2025-07-08RXRX5.3612.5- -1.46
2025-07-09RXRX5.5912.5- -1.46
2025-07-10RXRX5.7212.5- -1.46
2025-07-11RXRX5.2812.5- -1.46
2025-07-14RXRX5.2812.5- -1.46
2025-07-15RXRX5.2212.5- -1.46
2025-07-16RXRX5.3912.5- -1.46
2025-07-17RXRX5.5212.5- -1.46
2025-07-18RXRX5.8512.5- -1.46
2025-07-21RXRX6.3812.5- -1.46
2025-07-22RXRX6.5312.5- -1.46
2025-07-23RXRX6.4312.5- -1.46
2025-07-24RXRX6.2612.5- -1.46
2025-07-25RXRX6.4911.7- -1.46
2025-07-28RXRX6.2811.7- -1.46
2025-07-29RXRX5.9511.7- -1.46
2025-07-30RXRX5.8111.7- -1.46
2025-07-31RXRX5.9511.7- -1.46
2025-08-01RXRX5.6811.7- -1.46
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04RXRX-0.27-1.3138.65
2025-07-07RXRX-0.27-1.2938.65
2025-07-08RXRX-0.27-1.2938.65
2025-07-09RXRX-0.27-1.2938.65
2025-07-10RXRX-0.27-1.2938.65
2025-07-11RXRX-0.25-1.2935.52
2025-07-14RXRX-0.21-1.2635.52
2025-07-15RXRX-0.21-1.2635.52
2025-07-16RXRX-0.21-1.2635.52
2025-07-17RXRX-0.21-1.2635.52
2025-07-18RXRX-0.21-1.2635.52
2025-07-21RXRX-0.21-1.2935.52
2025-07-22RXRX-0.21-1.2935.52
2025-07-23RXRX-0.21-1.2935.52
2025-07-24RXRX-0.21-1.2935.52
2025-07-25RXRX-0.21-1.2934.95
2025-07-28RXRX-0.21-1.4034.95
2025-07-29RXRX-0.21-1.4034.95
2025-07-30RXRX-0.21-1.4034.95
2025-07-31RXRX-0.21-1.4034.95
2025-08-01RXRX-0.21-1.4034.95
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.5

Avg. EPS Est. Current Quarter

-0.35

Avg. EPS Est. Next Quarter

-0.32

Insider Transactions

-0.21

Institutional Transactions

-1.4

Beta

0.92

Average Sales Estimate Current Quarter

16

Average Sales Estimate Next Quarter

19

Fair Value

Quality Score

27

Growth Score

53

Sentiment Score

9

Actual DrawDown %

86.7

Max Drawdown 5-Year %

Target Price

6.67

P/E

Forward P/E

PEG

P/S

41.05

P/B

2.47

P/Free Cash Flow

EPS

-1.78

Average EPS Est. Cur. Y​

-1.46

EPS Next Y. (Est.)

-1.15

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-961.32

Relative Volume

0.63

Return on Equity vs Sector %

-85.3

Return on Equity vs Industry %

-66.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Recursion Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 800
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
stock quote shares RXRX – Recursion Pharmaceuticals, Inc. Stock Price stock today
news today RXRX – Recursion Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RXRX – Recursion Pharmaceuticals, Inc. yahoo finance google finance
stock history RXRX – Recursion Pharmaceuticals, Inc. invest stock market
stock prices RXRX premarket after hours
ticker RXRX fair value insiders trading